Paxlovid was approved by the FDA late last year for people and children 12 and older who are classified high risk. However, Pfizer’s COVID pill paxlovid shows no benefit in younger adults, according to a study.
- EXPLOSIVE: Here’s what was uncovered in Hunter Biden’s iCloud Hack
- MAJOR PEER REVIEWED STUDY: Moderna Vaccine Increases Myocarditis Risk By 44 Times In Young Adults
- MUST READ: High Level International Bankers Simulate The Collapse Of Global Financial System
- BIG STORY: Wuhan Lab Isolated Monkeypox Strain In 2020
- EXPLOSIVE: Ukraine Biolabs Used Fever Carrying Mosquitoes To Spark Dengue Pandemic In Cuba
President Biden, First Lady Jill Biden, and Dr. Anthony Fauci all started to experience “rare” rebound instances after taking Pfizer’s Covid-19 pill. According to the Washington Post, who cited an Israeli study that was released in the New England Journal of Medicine, Pfizer’s Covid-19 pill offers “little or no benefit for younger adults.”
Researchers discovered that although the medication, when taken soon after infection, lowered hospitalizations among individuals 65 and older by about 75%, it had no discernible effect on those between the ages of 40 and 65.
“Paxlovid will remain important for people at the highest risk of severe COVID-19, such as seniors and those with compromised immune systems,” said Dr. David Boulware, a University of Minnesota researcher and physician. “But for the vast majority of Americans who are now eligible, this really doesn’t have a lot of benefit.”
Paxlovid was approved by the FDA late last year for people and children 12 and older who are classified high risk, which comprises individuals who are obese, diabetics, or have heart disease. According to the CDC, more than 42% of US adults are obese, totaling around 138 million people.
Subscribe to GreatGameIndia
Earlier this summer, Pfizer admitted that an independent study of Paxlovid found no considerable impact in healthy adults, vaccinated or not.
According to federal records, just around 4 million prescriptions for the 5-day regimen have already been issued since its approval.
In an email to The Washington Post on Wednesday, White House spokesman Kevin Munoz attempted to defuse the situation for Pfizer by stating that new non-peer-reviewed studies show Paxlovid helps individuals 50 and older experience fewer hospitalizations.
“Risk for severe outcomes from COVID is along a gradient, and the growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid,” said Munoz.